Siemens Healthineers stock holds after July sales and guidance
Published on 08/21/2026 at 15:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Siemens Healthineers stock (DE000SHL1006) trades at EUR 39.58, with the shares down 0.81 percent on August 21, 2026 and still 11.03 percent lower for the year. The latest quoted average target is EUR 44.99, while the latest reported quarter brought EUR 5.76 billion in revenue and EUR 676 million in net income on July 31, 2026.
July 31 set the tone
The third-quarter update remains the key reference point for the stock. Revenue rose 2.8 percent year over year to EUR 5.76 billion, adjusted EPS came in at EUR 0.70, and management narrowed full-year revenue growth guidance to 3.5 percent to 4.0 percent from 4.5 percent to 5.0 percent.
That same update also lifted adjusted EPS guidance to EUR 2.35 to EUR 2.45 from EUR 2.20 to EUR 2.30, a change that was tied to tariff refunds rather than a broader change in the operating trend. The contrast between slower sales growth and higher earnings guidance helps explain why the share price has moved, but not decisively rerated.
Consensus still points higher
The current market view leaves room for debate. Consensus data shows 26 analysts with an average target price of EUR 44.99, which is 13 percent above the quoted share price of EUR 39.58, and the stock is still 19 percent below the 52-week high of EUR 49.78.
That gap is the most useful comparison for investors right now because it frames the argument in numbers, not mood. The shares also remain above the 52-week low of EUR 32.84, so the market is pricing a company that has recovered, but not fully repaired its outlook.
Buybacks add support
Share repurchases have provided a second support line. The company bought back another 50,000 shares between August 10 and August 16, bringing the total since June 1 to 2,824,371 shares.
For a stock trading below the average analyst target and above its low for the year, that buyback pace matters because it adds a steady bid while investors wait for the diagnostics business to prove that sales growth can reaccelerate.
Diagnostics remains the pressure point
The latest quarterly figures show why the market is still cautious. Revenue reached EUR 5.76 billion, but full-year growth guidance now points to 3.5 percent to 4.0 percent, and the revised earnings range of EUR 2.35 to EUR 2.45 per share leaves less room for disappointment than before.
Consensus EPS for the current fiscal year stands at EUR 2.36, which sits near the bottom of the guided range. That makes the next reporting date on November 5, 2026 the next hard checkpoint for whether the company can convert the guidance reset into a more convincing earnings path.
What the company sells
Siemens Healthineers builds imaging systems, diagnostics tools, and therapy equipment used across hospitals and laboratories. That mix explains why the diagnostics segment has become such an important swing factor for revenue growth and investor sentiment.
Stock level to watch
The stock was last quoted at EUR 39.58 on August 21, 2026, and the share price sits below the average target of EUR 44.99 but above the 52-week low of EUR 32.84.
Market profile
Company: Siemens Healthineers AG
ISIN: DE000SHL1006
Ticker: SHL
Exchange: Xetra
Price (as of August 21, 2026, 6:37 a.m. ET): EUR 39.58
Market cap: EUR 44.0 billion (as of August 21, 2026)
Sector / Industry: Health Care / Advanced Medical Equipment & Technology
Index membership: DAX
